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Hot salineAbstract Background: Endoscopic lung volume reduction maneuver using simple inexpensive
reagents to remodel and shrivel damaged regions of the lung has been accomplished in managing
human with pulmonary emphysema as a surrogate for surgical interference.
Objectives: Evaluation of the safety and efficacy of hot saline versus dissolved doxycycline
(vibramycin) for lung volume reduction of emphysematous lung in both adult and pediatric age
groups.
Patients and methods: Prospective clinical study was conducted on 21 patients with pulmonary
emphysema. They were submitted to fiberoptic bronchoscopy (FOB), chest computed tomography
(CT) and comprehensive respirometry. They were divided into two groups: group I underwent FOB
instillation of hot saline with 50 C in two consecutive sessions and group II underwent FOB instil-
lation with dissolved doxycycline in normal saline also in two consecutive sessions, and each pro-
cedure then repeated after one week.
Results: The total success rate of the procedure in group I was 72.72% and in group II 70%
however the total success rate in the studied cases was 71.43%. The procedure success in adult
age group in group I represented 77.7% on the other hand in group II it reached 75% and the total
therapeutic success rate was 76.74% while in the pediatric age group it accomplished an equal per-
centage (50%) in both groups.rculosis.
72 A.M. Abumossalam et al.Conclusion: Bronchoscopic lung volume reduction by hot saline and dissolved doxycycline
comes into sight to be a safe and feasible profile with an acceptable outcome that presents an attrac-
tive substitute to COPD patients who are physiologically friable.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is the most
common variety of primary pulmonary disablement [1] and
an important cause of mortality when become advanced. As
COPD becomes an end-stage disease, palliative surgical proce-
dures, such as bullectomy for giant bullae, lung volume reduc-
tion surgery (LVRS) and lung transplantation, are the only
impending treatments left over [2].
Studies conducted by Berger and Fishman have declared
that lung volume reduction surgery (LVRS) improves dyspnea,
increases exercise capacity, improves lung function, enhances
health-related quality-of-life events and reduces mortality in
selected patients with advanced emphysema [3,4]. Although
beneficial to many emphysema patients, LVRS is associated
with an operative mortality rate of 4–7%, a morbidity rate
of 30–50%, and an average hospital stay of 10–14 days [5,6].
The development of less invasive and less morbid advances
to lung volume reduction would represent a substantial pro-
gress in the treatment of emphysema [7]. Several broncho-
scopic procedures designed to reduce lung volume in patients
with emphysema are beneath research. These include one-
way valves, [8–12] or bronchial occlusive devices to deflate
emphysematous portions of the lung [13] and bronchial fenes-
tration with bypass stents [14] to improve expiratory flow.
Although some progress has been made using endobronchial
valves, published pilot studies [11] have revealed contradictory
alteration in pulmonary function. It is suggested that the wide-
ranging collateral ventilation present in emphysematous lungs
appears to limit the efficacy of endobronchial valves [15].
Biological agents aim to diminish lung volume via barricad-
ing the most emphysematous areas. The rapidly polymerizing
sealant is designed to work at the alveolar level rather than
in the airways. Their mechanism of action involves resorption
atelectasis rather than airway occlusion, subsequent airspace
inflammation, and then remodeling. This remodeling will lead
to scarring-induced contraction of lung parenchyma and func-
tional lung volume reduction can be expected within 6–8 weeks
[16]. The sealant causes blockage of interalveolar as well as
bronchiolar-alveolar collateral channels and contradicts the
effects of collateral ventilation. This approach aims to achieve
benefits by actual reductions in dead space that is physiologi-
cally similar to surgery [17].
Lung volume reduction aims to correct loss of elastic recoil
by reducing the volume of the most damaged lung segments
and allowing the remaining less damaged tissues to reformat.
By eliminating parts of the emphysematous lung with the long-
est expiratory time constants and removing dead space,
dynamic air trapping is reduced and exercise capacity can be
increased. The working length of respiratory muscles is also
normalized by restoring the normal dimensions of both the
chest wall and the diaphragm [18].Biological lung volume reduction appears to be secure and
a dosage-dependent response has been identified. In order to
achieve 20–30% of the lung volume that is removed in surgery,
up to 12 subsegments may need to be sealed in future efficacy
researches [17]. Unlike endobronchial valves, this therapy is
not easily reversible and long-term follow up data are critical.
There are also concerns that atelectasis may diminish with time
because of biodegradation of the hydrogel [19]. An interesting
parallel development has been the bronchoscopic injection of
autologous blood and fibrinogen into bulla to simulate volume
reduction [16].
In vapor steam LVR controlled bouts of steam, when deliv-
ered to a segmental airway, can produce an inflammatory
response that results in lung volume reduction. The advantage
of this technique is that no prosthesis needs to be inserted. A
non-reusable 2 mm vapor catheter is inserted via flexible bron-
choscopy to the identified airways. On the vapor catheter,
there is a distal occlusion balloon that isolates the lung seg-
ment. A precise amount of steam generated by an electroni-
cally controlled pressure vessel is then delivered to these
isolated airways. In a safety and feasibility trial, 11 patients
with heterogeneous emphysema were treated unilaterally with
a dose of 5 calories per gram of lung tissue [20]. So the aim of
this study was to evaluate the safety and efficacy of hot saline
versus dissolved doxycycline (vibramycin) for lung volume
reduction of the emphysematous lung.
Aim of work
The aim of the work was the evaluation of the safety and effi-
cacy of hot saline versus dissolved doxycycline (vibramycin)
for lung volume reduction of the emphysematous lung in both
adult and pediatric age groups.
Patients and methods
This prospective clinical study included 21 patients (17 chronic
obstructive pulmonary disease patients (COPD) >18 years; 15
male and 2 females admitted in chest department, Mansoura
University Hospital and 4 children; males <18 years (15-16-
17-15) with alpha one antitrypsin deficiency admitted at Man-
soura University Children Hospital (previously diagnosed by
establishment of low serum levels with determination of the
genotype and on regular follow up at outpatient clinic) during
the period from June 2014 to May 2015. This study was con-
ducted on patients to correlate the following standards:
Inclusion criteria
1. Emphysematous type of COPD.
2. Age 15–65 years.
Hot saline versus dissolved doxycycline for lung volume reduction 733. Dyspnea >grade 2 by Modified research Council scale on
routine daily activities despite maximal medical therapy.
4. Heterogeneous disease on CT chest.
5. Alpha one antitrypsin deficiency provided by serum level of
enzyme with genotype detection.
Exclusion criteria
1. FEV1 <20% of predicted value.
2. Hypercapnea with PaCO2 >55 mmHg.
3. Diffusion capacity DLCO <25% of predicted value.
4. Evidence of active pulmonary infection.
5. Patient cannot or will not comply with follow-up
investigations.
6. Contraindications to fiberoptic bronchoscope.
They were divided according to the method used for lung
volume reduction into two groups:
Group I
Physical pneumoplasty included 11 patients (9 of them
>18 years and 2 of them <18 years) who underwent medical
pneumoplasty (MP) with hot saline. Patients underwent 2 ses-
sions in two successive days (10 cm hot saline with 50 C) for
each segment and only one lung can be injected at one session
and the other lung can be injected in the second day.
The degree of hot saline 50 C was selected to be equivalent
to the degree of ablative thermal therapy utilized in direct tissue
destruction of tumor cells as the normal degree of lung tissue is
around 37 C, equivalent to normal body temperature [21].
Group II
Chemical pneumoplasty included 10 patients (8 of them
>18 years and 2 of them <18 years) who underwent medical
pneumoplasty (MP) with doxycycline (vibramycin) dissolved
with saline. Patients underwent 2 sessions in two successive
days with (2 capsules; 200 mg; dissolved in 10 cm of doxycy-
cline) for each segment and only one lung can be injected at
one session and the other lung can be injected in the second
day. Selecting doxycycline dose represents the minimal dose
that can induce mucosal injury [22].
Both groups carried out two successive sittings with one
week apart; the patient is exposed to the first sessions (either
hot saline or dissolved doxycycline) in two consecutive days
then exposed to the second session after one week with the
same procedure.
Procedure
Patients were managed in the operating room under conscious
sedation using short-acting IV agents (remifentanil or propo-
fol). Electrocardiogram, blood pressure, pulse and arterial
oxygen saturation levels were monitored throughout the proce-
dure. The patients were locally anesthetized with lidocaine oral
spray 5%. Arterial blood gas level determinations were
obtained from a radial artery before and after the procedure.
Following the patient preparation, a flexible bronchoscope(Pentax FB 19 TV; Tokyo, Japan) was introduced through
the mouth; oral approach. The upper pulmonary lobes in
one lung were reselected for lung volume reduction LVR treat-
ment followed by lower lung lobes. The bronchus leading to
the target segment was identified, and the bronchoscope was
then advanced into wedge position in order to prevent the back
return flow of LVR reagents. Wedging was tested by applying
suction and observing elevation of the negative suction moni-
tor degree. With the bronchoscope in a wedge position, the
LVR procedure was performed as follows. (1) For the first
group a total of 10 cm hot saline 0.9% with 50 C previously
deposited in boiled water till it reached the desired Celsius
degree measured by Celsius thermometer; for each segment
which was intended to deactivate the surfactant and promote
the detachment of epithelial cells, was instilled through the
working channel of the instrument (the amount prescribed
and used was 100 ml for the right lung and 90–100 for the left
lung according the number of segments). (2) For the second
group, a total of (2 capsules of doxycycline (vibramycine);
200 mg; dissolved in 10 cm for each segment and only one lung
can be injected at one session and the other lung can be
injected in the second day. The injectable reagent was left in
place and waiting for 2–5 min was conducted to evaluate the
retrieval if being bloody due to pulmonary capillarities. The
injectable substance was expected to promote inflammation
and microatelectasis, facilitating remodeling of the hyperin-
flated lung through scar tissue formation. The bronchoscope
was then positioned till the next treatment occasion, and the
sequence of delivery of LVR reagents was repeated the next
day for the other lung. The whole maneuver was conducted
again after one week. As a precaution, patients were moni-
tored overnight in the hospital. The primary safety endpoints
of this method were the incidence of adverse effects detected.
Complications encountered were haemoptysis, noncardiogenic
pulmonary edema, segmental pneumonitis, pneumonia, fever,
pneumothorax and commitment for mechanical ventilation.
By patient interviews, physical examinations, ECGs, radio-
logic imaging, pulmonary function test were conducted at zero
– 3 months of maneuver for procedure evaluation. Compre-
hensive respirometry was performed by Smart PFT Lab, Med-
ical Equipment Europe GmbH, Germany, 2011 in Mansoura
University Chest Department Respirometry Unit measuring
FEV1, FVC, TLC, PEFR, FET and DLCO. Spirometric eval-
uation was performed in three different sessions and the best
results were obtained on account of excluding inter-
individual variability both at zero measurement and final
3 month assessment.
Lung volumetery by CT chest
As a radiographic technique, CT chest offers the potential for
volume measurements of whole lung or specific regions or sec-
tions of lung. CT method utilizes the Volume Viewer (VV)
software that has a large number of possibilities, and the user
can quite freely choose how to use the program. In the end, the
volume is calculated as the sum of all voxels left in the picture.
This means that the user has to remove all unwanted structures
from the picture to get the true volume of the object. The Vol-
ume Viewer software can be used in different ways. CT chest
was performed in supine position, images were acquired with
a multislice Light Speed virtual CT (VCT) 64 scanner (General
74 A.M. Abumossalam et al.Electric, GEMS, Milwaukee, USA) with the following techni-
cal parameters: 1.25 mm collimation, 0.6-mm overlap, 0.5-s
rotation time, 120 mA and 120 kVp.
Thresholding is one of many available options. By setting
lower and upper thresholds, the user selects tissue within the
wanted density interval. Other possibilities are to keep one
specific object and eliminate all structures that are not con-
nected to it, in 3D, or to remove unwanted structures by letting
an erasing area grow. The erasing area is defined by the user
who puts the cursor on a voxel, with the mouse button pressed.
Voxels that are attached to that voxel will be selected. After
this, voxels connected to these will be selected and so on until
the user releases the button. At this moment all selected voxels
will be deleted. Two operations dilate and erosions are avail-
able. In this case the meaning is add (dilate) or ‘‘peel” (erosion)
from one up to 20 layers of voxels from the surface, and holes
inside, of the current 3D object. The structuring element is in
3D and gets bigger when more layers are wanted to get added
or peeled. It is also possible to invert the picture, to let all the
erased voxels be shown instead of the previously selected [23].
Selection criteria
Patients were selected in random sample according to the time
of medical consultation the former for group I and the latter
for group II, and approval of admission to the hospital with
signing on medical patient consent was given.
Procedure evaluation
The primary endpoint was death of the patients to restrain this
procedure and the secondary endpoints were considered as a
scale of summation of clinical, functional and radiological
parameters; above certain score >7 (that guarantees fulfill-
ment of 70%; at least 4 pulmonary functions parameters were
obtained) the procedure was considered successful and below
this score failure was the outcome. This scale performed for
patients at zero – 3 months visits; was estimated after the sec-
ond sitting.Assessment scale parameter Scoring
valueClinical criteria1. Improvement in MRC dyspnea scale =12. Frequency of exacerbations <2 per week =13. Hospital admissions <2 per month =1Functional criteria1. FEV1 improvement >12% =12. TLC decrement If >20% =13. DLCO improvement 20% =14. Arterial blood gases improvement (persistent
reduction of the level of hypoxemia from severe to
moderate or from moderate to mild on room air)=15. Forced expiratory time <6 s =16. Peak expiratory flow rate improvement (PEFR
measured by the average of three trials detect even
minimal degree of increase)=1Radiological criteriaReduction of total lung volume >10% by CT chest
(according to Coxson et al. [24])=1Score of the procedure:- total score = 10- Successful procedure: if the patients score more than 7
points (that guarantees fulfillment of 70%; at least 4 pul-
monary functions parameters were obtained).
- Failed procedure: if the patients score less than 7 points.
NB: 6 min walk test was not considered as most patients
expressed osteoarthritis and or osteomalacia or patient rebuttal.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 21. Qualitative data were presented as num-
ber and percentage. Quantitative data were presented for nor-
mality by Kolmogrov–Smirnov test. Normally distributed data
were presented as mean and standard deviation. Comparison
between groups was done using Chi-square test. A Student t-
test was used to compare between two groups. P value < 0.05
was considered significant.
Results
Table 1, shows that no documented statistical significance was
detected between hot saline and dissolved doxycycline in lung
volume reduction regarding secondary endpoints of assess-
ment scale parameters. In the same way, the percentage of
response of the patients for each monitoring parameter was
approximated between the two methods; nevertheless, most
of the parameters prevailed in hot saline group than doxycy-
cline group, apart from the frequency of hospital admission
and duration of forced expiratory time that dominated in
group II. The total success rate of the procedure in group I
was 72.72% and in group II 70% however the total success
rate in the studied cases was 71.43%.
As shown in Table 2 the procedure success in adult age
group in group I represented 77.7% on the other hand in
group II it reached 75% and the total therapeutic success rate
was 76.74% in while in the pediatric age group it accomplished
an equal percentage (50%) in both groups.
As shown in Table 3 out of the 21 cases 7 cases developed
complications (33.3%) that were detected in group I in the
form of one case developing pneumonia and another case
developing fever that resolved with nonspecific antimicrobial
and antipyretic for 3 days without any remains however, in
group II there was one case developing pneumonia one case
developing fever and another case developing noncardiogenic
pulmonary edema that necessitates mechanical ventilation
for 4 days and a fourth case presenting with unilateral infiltrate
without fever elevated C reactive protein or leucocytosis denot-
ing segmental iatrogenic pneumonitis that managed by steroid
for 5 days. No cases of mortality were recorded either during
or post-procedure within 3 months.
All complications were encountered after the second sitting
apart from haemoptysis and fever that were identified after the
two sittings.
Discussion
Every now and then, medical and surgical efforts are continu-
ously brought to bear for patients with pulmonary emphysema
Table 1 Demographic data and assessment scale parameters in studied cases.
Group I (hot saline) Group II (dissolved doxycycline) Total P value
N= 11 N= 10
Age group and sex
Adult group =8 Male + one female =7 Male + one female 21 (100%)
Children group =2 Males =2 Males
Improvement in MRC dyspnea scale 11 (100%) 10 (100%) 21 (100%) 0.432
Frequency of exacerbations <2/week 9 (81.81%) 7 (70%) 16 (76.1%) 0.310
Hospital admissions <2/month 8 (72.72%) 8 (80%) 16 (76.1%) 0.521
FEV1 improvement >12% 9 (81.81%) 8 (80%) 17 (80.9%) 0.241
TLC decrement >20% 8 (72.72%) 7 (70%) 15 (71.4%) 0.231
DLCO improvement 20% 8 (72.72%) 7 (70%) 15 (71.4%) 0.231
Pulse oximeter improvement 9 (81.81%) 7 (70%) 16 (76.1%) 0.310
FET <6 s 8 (72.72%) 8 (80%) 16 (76.1%) 0.521
PEFR improvement 9 (81.81%) 7 (70%) 16 (76.1%) 0.310
Reduction of lung volume >10% by CT chest 9 (81.81%) 7 (70%) 16 (76.1%) 0.310
Cases fulfilled score >7 points 8 (72.72%) 7 (70%) 15 (71.4%) 0.231
Total 72.72% 70% 71.43% 0.435
FEV1 = forced expiratory volume in first second, TLC= total lung capacity, DLCO= level of diffusion of carbon monoxide, FET = forced
expiratory time, PEFR= peak expiratory flow rate.
Table 2 Categorization of medical pneumoplasty success according to age group.
Group I (hot saline) Group II
(dissolved doxycycline)
Total P value
N= 11 N= 10
Adult age group (n= 17) 9 8 17 0.241
Successful procedure 7 (77.7%) 6 (75%) 13(76.74%) 0.356
Children age group (n= 4) 2 2 4 0.541
Successful procedure 1 (50%) 1 (50%) 2 (50%) 0.541
Table 3 Complications of medical pneumoplasty in studied
cases.
Group
I hot
saline
N= 11
GROUP II
dissolved
doxycycline
N= 10
Total
Non cardiogenic pulmonary
edema
0 1 1
Iatrogenic segmental pneumonitis 0 1 1
Pneumonia 0 0 0
Haemoptysis 1 1 2
Fever 1 1 2
Necessity for mechanical
ventilation
0 1 1
Pneumothorax 0 0 0
Bronchiolitis obliterans 0 0 0
Total 2 5 7
Hot saline versus dissolved doxycycline for lung volume reduction 75in order to minimize the respiratory suffer of them. The model
of non-resectional lung volume reduction has emerged not
long time ago. Many devices and strategies were innovated
to achieve endoscopic lung volume reduction without the call
for open surgery. These include iatrogenic segmental atelecta-
sis using endobronchial sealants, occluding and inflammatoryagents, or valves and creation of extra-anatomic tracts within
the major airway to facilitate expiratory phase of airflow.
Endoscopic iatrogenic lung volume reduction LVR is the
first-method biopharmaceutical that diminishes hyperinflation
by initiating a localized induced inflammatory reaction, which
collapses nonfunctional emphysematous lung. This reaction
may be associated with leukocytosis, fever, malaise, shortness
of breath, nausea, and pleuritic chest pain that develop in
the majority of treated patients. These systemic manifestations
of LVR therapy generally resolve within 24–48 h with support-
ive medical care including antipyretics, intravenous fluids and
antimicrobials. Criner, Pinto-Plata, Strange, et al. [25] showed
that LVR reagents instilled in eight segments can safely reduce
lung volumes and improve pulmonary function with an accept-
able side-effect profile, through the bronchoscopic coadminis-
tration of two liquid reagents that flow into the alveolar
compartment and polymerize. The resulting hydrogel collapses
and remodels the targeted lung region over 4–6 weeks. The
hydrogel’s physical properties and its site and mode of action
overcome the effects of collateral ventilation, which limit the
therapeutic effectiveness of endobronchial one-way valves
designed to promote lung volume reduction through regional
atelectasis [15,26]. There were no deaths during the course of
their study. LVR produced changes in lung anatomy through
biologic remodeling that were associated with improvements
in lung physiology.
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Figure 1 Diagram illustrates the percentages of scale parameters of assessment of LVR procedure success. FEV1 = forced expiratory
volume in first second, TLC = total lung capacity, DLCO= level of diffusion of carbon monoxide, FET = forced expiratory time,
PEFR= peak expiratory flow rate.
Figure 2 CT chest reformatting of (A) patient No. 1 performed LVR with hot saline showed reduced lung volume elevated
diaphragmatic copula and rounded atelectasis, (B) patient No. 4 performed LVR with dissolved doxycycline showed reduced lung volume
atelectatic areas, tracked areas.
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Hot saline versus dissolved doxycycline for lung volume reduction 77In our study, hot saline can induce thermal lung injury to
medium sized and alveolar lining membranes that induce
inflammatory reactions, in turn, enhance alveolar and bronchi-
olar scarring with partial microatelectasis that modifies the
segmental infrastructure declining the air trap and hence mod-
ifies the dynamic compression of hyperinflated lung. Staged
thermal pneumoplasty by hot saline can thereafter graduate
the hazard on temporary gas exchange impairment. On the
other hand using sclerosant agent like doxycycline also carries
the same idea of physical thermal pneumoplasty but through
augmenting a chemically powerful irritant effect on alveolar
and medium sized bronchioles with partial collapse to remodel
the terminal airways and so improve the patient compliance.
In our research clinical background depends on summation
of three clinical parameters that give surety about the actual
improvement of disease state in our patients and guard against
subjective variations. As for the analysis of the St George Respi-
ratory Questionnaire [25] results, comparisons of data were not
possible before 3 months, because some of the assessments
within the questionnaire cannot be fully answered until then.
In Criner study, 2009 [25] show the baseline values suggested a
generalized impairment of patients’ quality of life; the worst
result obtained was in the activity score. Statistically significant
improvements in all 4 domains measured were demonstrated at
90 days. Overall, 85% of the group that reported an improve-
ment of dyspnea at 30 days after the procedure with theMedical
ResearchCouncil dyspnea grademeasurement demonstrated an
improvement at 30 and 90 days (P= 0.006 and 0.003, respec-
tively), thus indicating a significant reduction in the symptoms.
In our work respirometric parameters showed that FEV1,
TLC, FET and DLCO were higher in hot saline group than
doxycycline one, on the other hand PEFR and pulse oximetry
were higher in doxycycline group and the total outcomes
exceeds 70% that can be relied upon as parameter of success
of the procedure (FEV1 = 80.9%, TLC = 71.4%,
DLCO= 71.4%, Pulse oximeter = 76.1% PEFR= 76.1%
and FET= 76.1%). By means of using certain cut off level
as FEV1>12% and TLC >20%, DLCO >20% ameliorate
the subjective chance of decision of functional improvement.
In accordance with Yim et al. [9] there were significant
improvements in the mean value of FEV1 (percentage of pre-
dicted) and forced vital capacity (percentage of predicted) at
each follow-up time point. The mean value of FEV1 was
improved by 15% at 30 days and by 26% at 90 days, and this
improvement was significant at 90 days (P= 0.009). The mean
value of forced vital capacity also increased and became statis-
tically significant at 90 days. Although there was a trend of
improvement in the mean DLCO value by 15% and 13% at
30 and 90 days, respectively, after the procedure, these changes
were not statistically significant. Likewise, lung volumes
demonstrated a reduction of the residual volume and the total
lung capacity, but the results did not reach statistical
significance.
Compared with surgical and alternative endobronchial
methods for achieving lung volume reduction, BioLVR
demonstrated an acceptable overall safety profile in patients
with severe emphysema. Serious pulmonary and cardiovascu-
lar complications within 30 days of treatment, defined as
respiratory failure, re-intubation post-procedure, clinically sig-
nificant hemoptysis, pneumonia, pulmonary embolus, cardiac
ischemia, or arrhythmias, have been observed in up to 58%of patients treated with LVRS, 8–10% of patients treated with
endobronchial valves, and 27% of patients treated with airway
bypass [27–30]. In the Criner, Pinto-Plata, Strange, et al., 2009
study [25] 4 of 50 patients (8%) treated with BioLVR experi-
enced such events. Although preliminary, these data suggest
that BioLVR has a safety profile that is better than LVRS,
and similar to other endobronchial lung volume reduction
methods.
Criner, Pinto-Plata, Strange, et al. [25,26] after Bio-LVR,
High resolution computed tomographic HRCT imaging
showed scarring and atelectasis at treatment sites confirming
the ability to endobronchially direct therapy to specific ana-
tomic locations. BioLVR responses, which correspond radio-
logically to sites of increased linear density, occurred only at
preselected target sites. Treatment was not associated with
mediastinal, pleural, or parenchymal pathology beyond the
anticipated remodeling reactions. Radiographic responses
were observed more consistently, and were larger in size after
high dose compared with low dose therapy of hydrogel, sug-
gesting a relationship between the degree of anatomic remod-
eling and magnitude of post-treatment physiological and
functional improvement. In a study by Yim et al. [9] three-
dimensional CT scans provide a very accurate estimate of lung
volume, and with thin CT thorax slices (collimation of 5 mm),
good follow-up images can provide an estimation of the degree
of emphysema in different segments of the lungs. Follow-up
thorax CT at both at 30 and 90 days is essential, because there
are cases of reexpansion and delayed collapse. In our study we
depended on single objective measurement with the intention
to rule out any subjective variability and avoid unintended bias
by disqualifying inter-observer and intra-observer variability.
Lung volumetry was detected by CT chest (computed tomog-
raphy of chest) before the procedure and after 3 months of
the bronchoscopic injection. Our patients showed only
81.81% in group I and 70% in group II atelectasis and volume
retraction with fine scarring more than 10% of the primary
lung volume or 300 ml according to Coxson et al. [24] regard-
ing both adult and pediatric age groups as shown in Fig. 2.
Yim et al. [9] experienced that in their study that a total of
17 patients with 23 targeted lobes had complete CT evaluation
at each follow-up for the degree of induced collapse. The
degree of collapse of the respective lobes seen in the CT scans
was categorized arbitrarily into 4 grades: grade 0 (0% col-
lapse), grade 1 (>25% collapse), grade 2 (25–75% collapse),
and grade 3 (>75% collapse). It is interesting to note that only
10 (43%) of the 23 lobes showed some degree of collapse dur-
ing the entire follow-up period. Six of these 10 lobes remained
unchanged throughout the follow-up period; whereas 2 lobes
showed mild re-expansion and the remaining 2 showed no col-
lapse at all in the first month but had a delayed collapse at the
third month.
Our patients showed that no documented statistical signif-
icance was detected between hot saline and dissolved doxycy-
cline in lung volume reduction regarding secondary
endpoints of assessment scale parameters. In the same way,
the percentage of response of the patients for each monitoring
parameter was approximate between the two methods; never-
theless, most of the parameters prevailed in the hot saline
group than doxycycline group, apart from the frequency of
hospital admission and duration of forced expiratory time that
dominated in group II. The total success rate of the procedure
78 A.M. Abumossalam et al.in group I was 72.72% and in group II 70% however the total
success rate in the studied cases was 71.43% as shown in Fig. 1.
According to Criner, Pinto-Plata, Strange, et al. [25] four
medical complications were defined as serious occurred over
69 treatment sessions. Procedure-related COPD exacerbations
were observed in 11 of 50 patients. All required hospitalization
and were clinically significant, but resolved with conventional
medical treatment and without long-term sequels.
In ours, exacerbations >2 week were documented in
18.18% in group I and 30% in group II and hospital admission
was observed in 23.9% of all studied cases. Among the 27
patients completing follow-up of Criner study out to 6 months
in the low dose group, the projected annual incidence of exac-
erbations between 1 and 6 months was 0.08 exacerbations per
patient per year. Among the 17 patients in the high dose group
completing follow-up over the same period, the projected
annual incidence of exacerbations was 0.28 exacerbations per
patient per year.
Out of our 21 cases 7 cases developed complications
(33.3%) that were in group I in the form of one case devel-
oping pneumonia and one case developing fever that
resolved with nonspecific antimicrobial and antipyretic for
3 days without any remains however, in group II there were
one case that developed pneumonia one case that developed
fever and another case that developed noncardiogenic pul-
monary edema that necessitates mechanical ventilation for
4 days and a fourth case presented unilateral infiltrate with-
out fever elevated C reactive protein or leucocytosis denot-
ing segmental iatrogenic pneumonitis that was managed by
steroid for 5 days with total improvement. No cases of mor-
tality was recorded either during or post-procedure within
6 months.
In the current research, as shown in Table 2 the procedural
success in the adult age group in group I represented 77.7% on
the other hand in group II it reached 75% while in the pedi-
atric age group it accomplished an equal percentage (50%)
in both groups. Up to our knowledge no literature stated the
efficacy of bronchoscopic lung volume reduction in the pedi-
atric age group. Having therapeutic efficacy of 50% of con-
ducted cases; despite this very small number of cases; it
encourages our motivation to carry out more and more
research in age below 18 years. Scarcity of cases of hyperin-
flated lung in children hinders this motive that necessitates
long term studies to be carried out.
Conclusion
Once in a while medical professionalism urges pulmonologists
to lend an accommodating hand to relieve the bearing of
breathlessness of emphysematous patients. Bronchoscopic
lung volume reduction by hot saline and dissolved doxycy-
cloine come into sight to be a safe, feasible profile with an
acceptable outcome that presents an attractive substitute to
COPD patients who are physiologically delicate. Also it can
help to wean patients off ventilators and may serve as overpass
to surgery or lung transplant. In contrast, minimal clinically
important differences in objective endpoints such as spirome-
try and radiological volumetry have been utilized as predictive
findings adjuvant to clinical stability. Refinement of patient
selection to identify optimal candidates for each individualendoscopic modality is likely to improve outcomes in future.
Our study documented that medical pneumoplasty has a total
therapeutic success rate of the procedure in the studied cases as
71.43%; (76.74% in adult while in the pediatric age group it
accomplished 50%). It is also wished that the ongoing, larger
randomized controlled trials will separate the therapeutic
effect of these procedures.
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